Mirum plans FDA submission for hepatitis D treatment as competition brews

Mirum’s hepatitis D treatment has succeeded in the second of two pivotal trials. Now comes the next challenge: competing with rivals in a growing market. The Phase 3 trial, called AZURE-4, enrolled 113 treatment-naïve patients ...